Biocytogen Pharmaceuticals-B (02315) plans to invest 1.6 billion yuan to build an animal center and preclinical CRO service experimental facilities.

Biocytogen Pharmaceuticals-B (02315) announced that with the rapid expansion of the company's animal model business and preclinical CRO services, as well as the increasing demand for innovative business brought by industry development trends, the existing animal center and preclinical CRO service experiment facilities of the company are difficult to meet the company's future development needs. The company plans to invest in the construction of animal centers and preclinical CRO service experiment facilities through its wholly-owned subsidiary, Biocytogen Pharmaceuticals Jiangsu Genetics Biotechnology Co., Ltd. (referred to as "Jiangsu Biotech"), with an investment amount of approximately 1.6 billion RMB (actual investment amount may vary). Through this investment construction project, the company will further expand the facility scale, increase production capacity supply, and better meet market demands. Additionally, taking advantage of its geographical location, the implementation of this investment construction project will facilitate a rapid response to the demands of customers in the surrounding areas and overseas for preclinical products and services. This investment construction project is centered around the company's main business, aligning with the company's long-term strategic development layout. It will help safeguard the further expansion of the company's business, enhance the company's core competitiveness, consolidate and develop the company's competitive advantage in the industry, and have positive strategic significance for the company's operations.